ORLANDO, Fla., June 1, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that subcutaneous injections of low doses of veltuzumab in patients with non-Hodgkin’s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) produced a slow and efficient delivery of pharmacologically active antibody into the blood, that the treatment was well tolerated, and that NHL patients showed objective responses at all doses tested.
